MedPath

A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level

Not Applicable
Conditions
Healthy adult
Registration Number
JPRN-UMIN000043321
Lead Sponsor
Pharma Foods International Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)Subject who is considered as a diabetes by a doctor. 2)Subject who is taking medication or under medical treatment. 3)Subject who is under exercise therapy or dietetic therapy. 4)Subject who has an allergy for test food. 5)Subject who has or had a history of either medicine or alcohol dependence syndrome. 6)Subject who has or had a history of mental illness(depression) or sleep disturbance. 7)Subject who is on a night-shift or is a shift worker. 8)Subject whose lifestyle is extremely irregular. 9)Subject who has an unbalanced diet. 10)Subject who is current disease or history of brain disorder, cancer, immunity disorder, diabetes, liver disease(hepatitis), kidney disease, serious disease such as heart disease, thyroid disease, adrenal disease, other metabolic diseases. 11)Subject who is use health foods, supplements, and medicines that may affect diabetes. 12)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study. 13)Subject who has blood drawn 200 mL within the past 1 months or 400 mL within the past 3 months from the day of the consent acquisition. 14)Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating. 15)Subject who can't keep the daily records. 16)Subject who is judged as an inappropriate candidate according to the screening data. 17)Subject who is considered as an inappropriate candidate by the doctor in charge.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Blood glucose *Measure at before ingestion and 15, 30, 45, 60, 90, and 120 minutes after ingestion. - Area Under the Curve
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath